Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MAOB | P27338 | 9/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436145 | 0.92 | THRB (0.65) | KMT2AMAOBNR1H4SMN1; SMN2MAOA | |
| SCHEMBL5974513 | 0.91 | MAOB (0.68) | KMT2AMAOBSMN1; SMN2MAOAMEN1 | |
| SCHEMBL17134301 | 0.90 | SMPD1 (0.69) | KMT2AMAOBNR1H4SMN1; SMN2SMPD1 | |
| SCHEMBL10498884 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL1436250 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL10885907 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL10497708 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL10497658 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL14189708 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 | |
| SCHEMBL11439572 | 0.89 | SMPD1 (0.72) | KMT2AMAOBNR1H4SMPD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| EP-2885306-B1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2885306-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014026881-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| EP-0699069-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0612244-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994025013-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0612244-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0550576-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1993008799-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| EP-0466408-A1 | N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides and processes for their production | ROHM AND HAAS COMPANY (US) | 1992-01-15 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | KMT2A 4556/4885MAOB 1091/4885NR1H4 639/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | KMT2A 4556/4885MAOB 1091/4885NR1H4 639/4885 |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | MAPT, SNCA, PARK7 | KMT2A 4778/4885MAOB 1114/4885NR1H4 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.